Relief Therapeutics Holding AG (RLFTF)

[Andy2018]

Manufacturing is established for mass production.

https://relieftherapeutics.com/relief-therapeutics-and-neurorx-announce-final-manufacturing-validation-of-rlf-100-for-phase-2b3-clinical-trial-in-patients-with-covid-19-associated-acute-respiratory-distress-syndrome/

GENEVA and RADNOR, PA., May 14, 2020 – RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. announced today that NeuroRx has completed final manufacturing of investigational drug RLF-100 for Phase 2b/3 clinical trial to assess intravenous RLF-100 as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients on mechanical ventilation.

Bachem Americas (Torrance, Calif.) and MedisourceRx (Encinatas, Calif.) respectively manufactured RLF-100 drug substance and drug product under the supervision of NeuroRx scientists Richard Siegel, Ph.D., and Robert Besthof MIM who previously held leadership positions at Johnson & Johnson and Pfizer prior to joining NeuroRx. Manufacture and release of investigational product was completed within 60 days of FDA’s approval to proceed with the clinical trial.

MedisourceRx (Encinatas, Calif.)
https://www.medisourcerx.com/news


Bachem Americas (Torrance, Calif.)
https://www.bachem.com/news-media/press-releases/